Multiple Myeloma: Understanding Its Higher Incidence and Impact in People of Color

Multiple myeloma, a rare cancer affecting plasma cells in the bone marrow, presents a complex and concerning picture, particularly for people of color. While it's not a common diagnosis, especially in younger individuals, its prevalence and impact are disproportionately higher in certain communities. Understanding these disparities is the first step towards addressing them and ensuring equitable care for all.

What is Multiple Myeloma?

Multiple myeloma (MM) is a cancer that originates in the plasma cells, a vital component of our immune system. These cells normally produce antibodies to fight off infections from bacteria and viruses. When MM takes hold, it disrupts this crucial function, leading to a reduced ability to combat illness. This makes individuals with MM more susceptible to recurring infections, a significant concern for their overall health.

The disease typically affects older adults, with the vast majority of diagnoses occurring in individuals over 65. It's exceedingly rare in younger populations; fewer than 1% of MM cases are found in people aged 35 and under. While males tend to develop MM slightly more often than females, other risk factors can also play a role.

The MGUS Connection: A Precursor to Myeloma

Before MM develops, many individuals experience a blood abnormality known as Monoclonal Gammopathy of Undetermined Significance (MGUS). This condition is characterized by the presence of an abnormal protein in the blood, but it doesn't meet the criteria for full-blown MM. MGUS itself doesn't cause symptoms and is considered premalignant, meaning it has the potential to become cancerous.

For some, MGUS can progress to smoldering multiple myeloma (SMM), and eventually, to MM. However, it's important to remember that many people with MGUS or SMM never develop cancer. Only a small percentage will go on to develop malignant MM. The significance of MGUS lies in its prevalence; it's found more often and diagnosed at earlier ages in Black Americans compared to the general population. This increased incidence of MGUS is a key factor contributing to the higher MM diagnosis rates in this group.

Disparities in Incidence: The Stark Reality

The statistics surrounding multiple myeloma reveal a stark disparity. Black Americans are diagnosed with MM at twice the rate of white Americans. As of 2018 data, myeloma diagnosis rates per 100,000 people were approximately 14.6 for Black individuals (including Hispanic) and significantly lower for other groups, such as American Indian and Alaska Native individuals at 7.6. This dramatic difference necessitates a closer examination of the underlying causes.

Potential Contributing Factors

Several factors are believed to contribute to the higher incidence of MM in Black communities:

• Genetic Predisposition: Research suggests a higher heritable prevalence of MM and MGUS within Black families compared to white families. Studies indicate that Black individuals are more likely to have specific genetic markers, such as immunoglobulin heavy chain gene translocations on chromosome 14, which are associated with an increased risk of MM.
• Environmental and Lifestyle Factors: Conditions like obesity and type 2 diabetes (T2D) have a higher prevalence in the Black American population. These conditions themselves are linked to an increased risk of MM, potentially explaining some of the observed disparities.
• Healthcare Access and Disparities: Unequal access to quality healthcare, including preventative screenings, timely diagnosis, and advanced treatment options, can significantly impact outcomes. Systemic issues and socioeconomic factors can create barriers to care, exacerbating the problem.

Understanding Genetic Markers and Prognosis

While certain genetic factors increase the risk, others may offer a more favorable prognosis for Black individuals diagnosed with MM. For instance, research indicates that Black individuals are less likely to have a deletion of the TP53/17p gene, which is an indicator of more aggressive cancer and a poorer survival rate. Furthermore, they are less likely to have monosomy 13 and monosomy 17, which are important prognostic markers used to guide treatment decisions. These genetic differences, while complex, suggest that when equal access to care is provided, Black patients may have a better outlook than their white counterparts.

Symptoms to Watch For

Because MM affects plasma cells and bone marrow, its symptoms can manifest in various ways. Early symptoms can be subtle and easily mistaken for other conditions. It's vital to be aware of potential signs:

• Bone Pain: Often felt in the back, ribs, or hips, this is a common symptom.
• Fatigue and Weakness: Due to anemia (low red blood cell count) caused by the cancer affecting bone marrow.
• Frequent Infections: A weakened immune system makes individuals more prone to infections.
• Kidney Problems: MM can affect kidney function.
• Increased Calcium Levels (Hypercalcemia): This can lead to nausea, vomiting, constipation, and confusion.
• Unexplained Weight Loss.
• Numbness or Tingling: Especially in the legs.

Diagnosis: A Multifaceted Approach

Diagnosing MM involves a combination of tests to assess the extent of the disease and its impact on the body:

• Blood Tests: To check for abnormal proteins (M protein), anemia, high calcium levels, and kidney function.
• Urine Tests: To detect M protein and assess kidney damage.
• Bone Marrow Biopsy: A sample of bone marrow is taken to examine plasma cells directly.
• Imaging Tests: Such as X-rays, CT scans, MRIs, and PET scans to check for bone damage and disease spread.

Treatment Options

Treatment for MM is tailored to the individual's specific situation, considering the stage of the disease, overall health, and genetic factors. Treatment aims to control the cancer, manage symptoms, and improve quality of life.

Common treatment approaches include:

• Chemotherapy: Drugs to kill cancer cells.
• Targeted Therapy: Medications that target specific molecules involved in cancer cell growth.
• Immunotherapy: Treatments that help the immune system fight cancer.
• Stem Cell Transplant: High-dose chemotherapy followed by the infusion of healthy stem cells.
• Radiation Therapy: To target specific areas of bone pain or tumors.
• Supportive Care: Medications for bone health, managing infections, and alleviating symptoms.

Prevention and Early Detection

Currently, there are no definitive ways to prevent MM. However, addressing modifiable risk factors can play a role:

• Maintain a Healthy Weight: Managing obesity can reduce the risk of associated conditions like T2D.
• Healthy Diet: A balanced diet rich in fruits, vegetables, and whole grains supports overall health.
• Regular Exercise: Promotes general well-being and can help manage weight.
• Awareness of Family History: If there's a history of MM or MGUS in the family, discuss this with your doctor.

Early detection is paramount. If you belong to a group with a higher risk or experience any of the symptoms mentioned, seeking medical attention promptly is essential.

When to Consult a Doctor

Don't ignore persistent symptoms like unexplained bone pain, fatigue, recurrent infections, or kidney issues. If you have a family history of multiple myeloma or MGUS, or if you are a Black individual experiencing concerning symptoms, it is vital to consult a doctor. Early diagnosis leads to more effective treatment and potentially better outcomes.

FAQs

Can multiple myeloma be cured?

While there is no definitive cure for multiple myeloma, it can often be managed effectively with treatment, allowing many individuals to live for years with a good quality of life. The goal of treatment is to control the cancer and its symptoms.

Is MGUS always a precursor to multiple myeloma?

No, MGUS is not always a precursor to multiple myeloma. Many people with MGUS never develop cancer. However, it does indicate an increased risk, and regular monitoring by a doctor is recommended.

Are there specific clinical trials for Black individuals with multiple myeloma?

Yes, efforts are underway to increase representation of diverse populations in clinical trials. Discussing participation in clinical trials with your oncologist is important, as these trials can offer access to new and potentially effective treatments. Ensuring diverse participation helps researchers understand how treatments work across different groups.

How can I support someone with multiple myeloma?

Support can come in many forms: emotional encouragement, practical help with daily tasks, accompanying them to appointments, and ensuring they have access to reliable information and resources. Listening and being present are invaluable.